No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Phase III Study Confirms Equivalence of Mabwell’s Denosumab Biosimilar with Amgen’s Xgeva®
A study sponsored by Mabwell (Shanghai) Bioscience Co Ltd and published in JAMA Oncology reports that the results of Chinese randomized, 53-week, phase III trials of Mabwell’s MW032 with Amgen’s Xgeva® in patients with solid tumor-related bone metastases, confirm...